首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1424960

熱原測試的全球市場：市場規模和份額分析（按產品、類型、最終用戶） - 工業需求預測（截至 2030 年）

Pyrogen Testing Market Size and Share Analysis by Offering, Type, End User - Global Industry Demand Forecast to 2030

出版日期: 2023年12月01日 | 出版商:

Prescient & Strategic Intelligence | 英文 310 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球熱原測試市場收入達到 14.064 億美元，預計 2024 年至 2030 年複合年增長率為 7.3%，達到 22.842 億美元。該市場的成長歸因於生物製藥領域對熱原測試的接受度不斷提高。

此外，生物技術和製藥行業的不斷發展，以及新生物製劑研究和行銷的增加，預計將推動對這些測試的需求，以生產更安全、更好的藥物。

熱原測試是使每種藥物和治療劑更安全、更有效的重要一步。癌症病例和遺傳性疾病數量的迅速增加導致了治療方法的改進，在這些疾病的治療中取得了成效。

個人化醫療的優點在於利用人們的基因圖譜來幫助做出有關疾病預防、診斷和治療的決策。因此，患者和公司正在迅速接受改進的藥物。此外，基於臨床和基因組特徵的改良治療在癌症和免疫疾病患者中越來越受歡迎。因此，改良藥物的需求不斷增加是推動熱原測試解決方案需求的主要原因之一。

從最終用戶來看，製藥和生物技術公司將在 2023 年佔據收入的最大份額，達到 35%，並且這一趨勢預計將持續下去。這是由藥品、生物製品和新藥產量的增加以及熱原測試需求的增加所推動的。此外，該類別的市場成長是由於對個人化醫療的日益偏好、傳染病和慢性病盛行率的增加而推動的。

北美地區2023年銷售量增幅最高，市佔率最高為55%。這是由於生物技術和製藥的持續成長。我們使用 cookie 來改善您的體驗。促進該地區市場成長的其他關鍵因素包括擴大處方藥管道、增加藥品審批以及提高產品安全和食品安全意識。

在北美地區，美國在該產業佔據主導地位。其主要原因是先進的醫療基礎設施、對新藥開發的關注以及輝瑞和羅氏等主要生物技術和生物製藥公司的存在。

此外，加拿大對北美工業也有顯著的好處。這是由於該國製藥和生物技術行業的崛起、藥品安全意識的增強以及研發活動的增加。

本報告分析了全球熱原測試市場，包括市場的基本結構和最新情況、主要促進和抑制因素以及全球、按地區和主要國家的市場規模前景（以貨幣形式計算），（2017-2030 ），按類型、用途、動物和最終用戶劃分的詳細趨勢、當前市場競爭狀況以及主要公司概況。

摘要
市場收入：依類型劃分（2017-2030 年）
市場收入：依應用分類（2017-2030 年）
- 外科手術市場收入：按類型劃分（2017-2030 年）
市場收入：以動物分類（2017-2030 年）
市場收入：以最終用戶劃分（2017-2030 年）
市場收入：按地區劃分（2017-2030 年）

第七章北美市場

摘要
市場收入：依類型劃分（2017-2030 年）
市場收入：依應用分類（2017-2030 年）
- 外科手術市場收入：按類型劃分（2017-2030 年）
市場收入：以動物分類（2017-2030 年）
市場收入：以最終用戶劃分（2017-2030 年）
市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第 11 章中東與非洲 (MEA) 市場

第12章美國市場

摘要
市場收入：依類型劃分（2017-2030 年）
市場收入：依應用分類（2017-2030 年）
- 外科手術市場收入：按類型劃分（2017-2030 年）
市場收入：以動物分類（2017-2030 年）
市場收入：以最終用戶劃分（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

市場參與者及其提供的產品/服務列表
主要公司的競爭基準
各大公司的產品基準
近期策略發展狀況

第30章公司簡介

Charles River Laboratories International Inc.
Merck KGaA
Thermo Fisher Scientific Inc.
FUJIFILM Wako Pure Chemical Corporation
WuXi AppTec Co. Ltd.
Microcoat Biotechnologie GmbH
Nelson Laboratories LLC
Lonza Group Ltd.
Ellab A/S
GenScript Biotech Corporation

第31章附錄

簡介目錄

Product Code: 12785

Revenue of USD 1,406.4 million was generated in the global Pyrogen Test Market for 2023, which is expected to grow at a compound annual growth rate of 7.3% over the period from 2024 to 2030 and reach USD 2,284.2 million. This growth of the market can be credited to the increasing acceptance of pyrogen testing within the biopharmaceutical sector.

Furthermore, the rising development in the biotechnology and pharmaceutical industries along with the increasing count of new biologics research and introductions is projected to fuel the demand for these testing for making safe and better drugs.

Pyrogen testing is a vital step for each medication and therapeutics to make it safer and more effective. Surge in the count of cancer cases and hereditary illnesses, modified treatments attained benefits in the treatment of these diseases.

Tailored medicine has the benefit that it uses people's hereditary profiles to aid in decision-making for the prevention, diagnosis, and treatment of illnesses. Therefore, patients and businesses are quickly accepting modified drugs. Furthermore, modified treatment-based methods to clinical and genomic features are becoming more popular among patients with cancer and immunologic sicknesses. Hence, the increasing need for modified drugs is one of the key reasons propelling the demand for pyrogen testing solutions.

On the basis of the end user, the category of pharmaceutical and biotechnology companies accounted for the largest revenue share of 35% in 2023 and is expected to remain so in the future. This has been driven by the increase in the manufacturing of medicines, biologics, and new drugs as well as a growing demand for pyrogen testing. In addition, the market growth in this category is being driven by a growing preference for personalized medicine as well as an increasing incidence of infectious and chronic diseases.

The foremost sales generator in 2023, North America accounted for the highest market percentage of 55%. That is due to the continuing growths in biotechnology and pharmaceutical wherein cookies are used to make your experience better. Other key factors that have contributed to the increase of the local marketplace consist of an extended pipeline of prescribed drugs, an upward thrust in drug approvals as well as growing awareness about product safety and food security.

In the North American region, the U.S. dominates the industry. This is mainly because of the existence of advanced healthcare infrastructure, augmented concentration on new drug growth, and the presence of key biotechnology and biopharmaceutical companies, like Pfizer Inc. and F. Hoffmann-La Roche AG, in the country.

Furthermore, Canada is also generating substantial revenue for the North American industry. This can be credited to the rising pharmaceutical and biotechnology sector, the rising awareness regarding the safety of medications, and the growing R&D activities in the country.

Top Providers of Pyrogen Testing Are:

Charles River Laboratories International Inc.

Merck KGaA

Thermo Fisher Scientific Inc.

FUJIFILM Wako Pure Chemical Corporation

WuXi AppTec Co. Ltd.

Microcoat Biotechnologie GmbH

Nelson Laboratories LLC

Lonza Group Ltd.

Ellab A/S

GenScript Biotech Corporation

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by type
- 1.4.2. Market size breakdown, by application
- 1.4.3. Market size breakdown, by animal
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by region
- 1.4.6. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Revenue, by Type (2017-2030)
6.3. Market Revenue, by Application (2017-2030)
- 6.3.1. Surgery market revenue, by type (2017-2030)
6.4. Market Revenue, by Animal (2017-2030)
6.5. Market Revenue, by End User (2017-2030)
6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Revenue, by Type (2017-2030)
7.3. Market Revenue, by Application (2017-2030)
- 7.3.1. Surgery market revenue, by type (2017-2030)
7.4. Market Revenue, by Animal (2017-2030)
7.5. Market Revenue, by End User (2017-2030)
7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Revenue, by Type (2017-2030)
8.3. Market Revenue, by Application (2017-2030)
- 8.3.1. Surgery market revenue, by type (2017-2030)
8.4. Market Revenue, by Animal (2017-2030)
8.5. Market Revenue, by End User (2017-2030)
8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Revenue, by Type (2017-2030)
9.3. Market Revenue, by Application (2017-2030)
- 9.3.1. Surgery market revenue, by type (2017-2030)
9.4. Market Revenue, by Animal (2017-2030)
9.5. Market Revenue, by End User (2017-2030)
9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Revenue, by Type (2017-2030)
10.3. Market Revenue, by Application (2017-2030)
- 10.3.1. Surgery market revenue, by type (2017-2030)
10.4. Market Revenue, by Animal (2017-2030)
10.5. Market Revenue, by End User (2017-2030)
10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Revenue, by Type (2017-2030)
11.3. Market Revenue, by Application (2017-2030)
- 11.3.1. Surgery market revenue, by type (2017-2030)
11.4. Market Revenue, by Animal (2017-2030)
11.5. Market Revenue, by End User (2017-2030)
11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

12.1. Overview
12.2. Market Revenue, by Type (2017-2030)
12.3. Market Revenue, by Application (2017-2030)
- 12.3.1. Surgery market revenue, by type (2017-2030)
12.4. Market Revenue, by Animal (2017-2030)
12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

13.1. Overview
13.2. Market Revenue, by Type (2017-2030)
13.3. Market Revenue, by Application (2017-2030)
- 13.3.1. Surgery market revenue, by type (2017-2030)
13.4. Market Revenue, by Animal (2017-2030)
13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

14.1. Overview
14.2. Market Revenue, by Type (2017-2030)
14.3. Market Revenue, by Application (2017-2030)
- 14.3.1. Surgery market revenue, by type (2017-2030)
14.4. Market Revenue, by Animal (2017-2030)
14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

15.1. Overview
15.2. Market Revenue, by Type (2017-2030)
15.3. Market Revenue, by Application (2017-2030)
- 15.3.1. Surgery market revenue, by type (2017-2030)
15.4. Market Revenue, by Animal (2017-2030)
15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

16.1. Overview
16.2. Market Revenue, by Type (2017-2030)
16.3. Market Revenue, by Application (2017-2030)
- 16.3.1. Surgery market revenue, by type (2017-2030)
16.4. Market Revenue, by Animal (2017-2030)
16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

17.1. Overview
17.2. Market Revenue, by Type (2017-2030)
17.3. Market Revenue, by Application (2017-2030)
- 17.3.1. Surgery market revenue, by type (2017-2030)
17.4. Market Revenue, by Animal (2017-2030)
17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

18.1. Overview
18.2. Market Revenue, by Type (2017-2030)
18.3. Market Revenue, by Application (2017-2030)
- 18.3.1. Surgery market revenue, by type (2017-2030)
18.4. Market Revenue, by Animal (2017-2030)
18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

19.1. Overview
19.2. Market Revenue, by Type (2017-2030)
19.3. Market Revenue, by Application (2017-2030)
- 19.3.1. Surgery market revenue, by type (2017-2030)
19.4. Market Revenue, by Animal (2017-2030)
19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

20.1. Overview
20.2. Market Revenue, by Type (2017-2030)
20.3. Market Revenue, by Application (2017-2030)
- 20.3.1. Surgery market revenue, by type (2017-2030)
20.4. Market Revenue, by Animal (2017-2030)
20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

21.1. Overview
21.2. Market Revenue, by Type (2017-2030)
21.3. Market Revenue, by Application (2017-2030)
- 21.3.1. Surgery market revenue, by type (2017-2030)
21.4. Market Revenue, by Animal (2017-2030)
21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

22.1. Overview
22.2. Market Revenue, by Type (2017-2030)
22.3. Market Revenue, by Application (2017-2030)
- 22.3.1. Surgery market revenue, by type (2017-2030)
22.4. Market Revenue, by Animal (2017-2030)
22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

23.1. Overview
23.2. Market Revenue, by Type (2017-2030)
23.3. Market Revenue, by Application (2017-2030)
- 23.3.1. Surgery market revenue, by type (2017-2030)
23.4. Market Revenue, by Animal (2017-2030)
23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

24.1. Overview
24.2. Market Revenue, by Type (2017-2030)
24.3. Market Revenue, by Application (2017-2030)
- 24.3.1. Surgery market revenue, by type (2017-2030)
24.4. Market Revenue, by Animal (2017-2030)
24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

25.1. Overview
25.2. Market Revenue, by Type (2017-2030)
25.3. Market Revenue, by Application (2017-2030)
- 25.3.1. Surgery market revenue, by type (2017-2030)
25.4. Market Revenue, by Animal (2017-2030)
25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

26.1. Overview
26.2. Market Revenue, by Type (2017-2030)
26.3. Market Revenue, by Application (2017-2030)
- 26.3.1. Surgery market revenue, by type (2017-2030)
26.4. Market Revenue, by Animal (2017-2030)
26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

27.1. Overview
27.2. Market Revenue, by Type (2017-2030)
27.3. Market Revenue, by Application (2017-2030)
- 27.3.1. Surgery market revenue, by type (2017-2030)
27.4. Market Revenue, by Animal (2017-2030)
27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

28.1. Overview
28.2. Market Revenue, by Type (2017-2030)
28.3. Market Revenue, by Application (2017-2030)
- 28.3.1. Surgery market revenue, by type (2017-2030)
28.4. Market Revenue, by Animal (2017-2030)
28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings
29.2. Competitive Benchmarking of Key Players
29.3. Product Benchmarking of Key Players
29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Charles River Laboratories International Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
30.2. Merck KGaA
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
30.3. Thermo Fisher Scientific Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
30.4. FUJIFILM Wako Pure Chemical Corporation
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
30.5. WuXi AppTec Co. Ltd.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
30.6. Microcoat Biotechnologie GmbH
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
30.7. Nelson Laboratories LLC
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
30.8. Lonza Group Ltd.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
30.9. Ellab A/S
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
30.10. GenScript Biotech Corporation
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary